| Line Item | 2026-04-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| SG&A Expense | $6K | -69.3% | -47.9% |
| Operating Income | -$19K | -1280.8% | +68.4% |
| Interest Expense | $19K | — | +256.0% |
| Pre-tax Income | -$25K | +99.4% | +62.1% |
| Income Tax | $0 | — | — |
| Net Income | -$4.4M | -1.7% |
| Line Item | 2026-04-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $59 | +0.0% | — |
| Current Assets | $59 | +0.0% | -89.9% |
| Total Assets | $59 | +0.0% | -89.9% |
| Current Liabilities | $443K | +6.0% | +10.0% |
| Total Liabilities | $443K | +6.0% | +10.0% |
| Stockholders' Equity |
| Line Item | 2026-04-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$63K | — | — |
| Financing Cash Flow | $62K | — | — |
Business Overview
Quantum Genesis AI Corp. (formerly Quantumzyme Corp.) develops enzyme catalyst biotransformation technologies and holds proprietary intellectual property including enzyme design technologies and computational methodologies acquired in February 2023. The company changed its name in February 2026 to reflect a strategic pivot toward artificial intelligence and enzyme design. The company is currently pre-revenue with no sales during the periods presented and is focused on formalizing IP ownership through an assignment agreement with its Chief Executive Officer.
Segment Performance
The company operates as a single reportable business segment with no revenue generation during any periods presented. Operating expenses for the nine months ended April 30, 2026 totaled $59,661 (compared to $145,921 for the prior nine-month period), consisting of general and administrative expenses of $25,029 and professional fees of $34,632. The company recorded a significant loss on conversion of debt of $4,325,872 during the nine months ended April 30, 2026, resulting from the issuance of 2,010,000 common shares valued at $4,401,900 to settle $60,300 in note payable and $15,728 in accrued interest.
Forward Guidance
The company's forward-looking statements are limited and cautionary in nature. The filing states: "Our actual results and financial condition may differ materially from those indicated in the forward-looking statements" and "you should not rely on any of these forward-looking statements." Regarding future operations, the company notes: "We are entirely dependent on our ability to attract and receive funding from either the sale of securities or outside sources such as private investment or a strategic partner. We currently have no firm agreements or arrangements with respect to any such financing and there can be no assurance that any needed funds will be available to us on acceptable terms or at all." No specific financial targets or guidance for future periods is provided.
| -6597.4% |
| EPS (Diluted) | $0.00 | +100.0% | — |
| -$443K |
| -6.0% |
| -10.1% |
Key Risk Factors
The company faces substantial doubt regarding its ability to continue as a going concern, having incurred net losses of $4.4 million for the nine months ended April 30, 2026, with accumulated deficits of $10.0 million and minimal cash of $59. The company is entirely dependent on attracting external funding with no firm financing agreements in place, and any equity financing would cause substantial dilution to existing shareholders. Additionally, there is uncertainty regarding the company's rights to its core intellectual property, as the patent application for Modified Polypeptides for Enzymatic Synthesis of Ibuprofen was filed in the Chief Executive Officer's name rather than the company's name.